Amy joined Kilburn and Strode in February 2021, having previously worked for four years at another private practice firm. She is a UK and European Patent Attorney. She has experience working with a broad range of technologies across the life sciences, including bispecific antibodies, mRNA therapies, genomic profiling, manufacturing and diagnostics. Amy has handled prosecution of patent applications relating to these technologies both in Europe and internationally. 

Amy holds a BSc and PhD in Neuroscience from University College London. Prior to training as a patent attorney she worked as part of an interdisciplinary research consortium investigating the genetic basis of Alzheimer’s Disease risk in Down Syndrome. Her thesis examined ways in which dysregulated gene expression contributes to increased seizure risk and synaptic dysfunction. 
 
Amy also carried out three further research projects as part of a her 4-year PhD programme, and undertook research internships in the UK and Germany during her undergraduate studies. Consequently, she has first-hand experience across a range of disciplines including molecular biology, genetics, pharmacology, cellular neuroscience, electrophysiology and behavioural neuroscience. 
 
Amy is enthusiastic about the role of technology in life sciences and has written several articles on the role of AI and machine learning in biotechnology.

Qualifications

Chartered UK Patent Attorney (2020)
PhD Clinical Neuroscience – UCL Institute of Neurology (2016)
BSc Neuroscience – University College London (2012)
 

Memberships

Chartered Institute of Patent Attorneys (CIPA)

Cookies improve the way our website works. By using this website you are agreeing to our use of cookies. For more information see our cookie policy I accept